Fluidiconic Biotechnology is a spin-off from National Tsing Hua University (Taiwan) developing MedSelect™, a state-of-the-art tumor-on-a-chip and automated drug-screening platform. 

The company enables pharmacies and CRO partners to shorten preclinical oncology testing cycles, reduce reliance on animal studies, and improve clinical translation through physiologically relevant tumor modeling. Leveraging patented microfluidic technology, automated analysis, and strong clinical and CRO partnerships, Fluidiconic is building a structured drug response and transcriptomic and genomic database to power next-generation AI assisted drug design and prioritization. 

The MedSelect platform further supports patient-derived samples for Phase-0–like testing, enabling a continuous workflow from AI-generated candidates to real-world tumor validation. Fluidiconic aims to establish MedSelect as the global gold standard for anticancer drug evaluation and precision oncology R&D. 

Fluidiconic Biotechnology develops MedSelect™, a next-generation tumor-on-a-chip platform that accelerates and improves the accuracy of preclinical anticancer functional  and drug efficacy testing.

Through a patented microfluidic architecture, programmable pneumatic pumps, and automated optical analytics, MedSelect reconstructs essential tumor microenvironment features, including hypoxia gradients, immune-cell infiltration, and stromal fibrosis, to more realistically predict in vivo drug responses. The system supports both high-throughput early-stage compound screening and IND-enabling patient-derived tumor studies. 

Beyond the platform itself, Fluidiconic is establishing standardized methodologies for diverse drug-testing applications, such as dose-response validation, immunotherapy evaluation, and combination-therapy analysis. 

The company is also building a longitudinal database linking patient treatment history, genomic data, and on-chip functional responses, laying the foundation for future data assetization and AI assisted drug-development tools.

1. Partnership with MD-PhD, KOL from Research unis for data validation from projects and studies.

2. Build network connection with US local lab or bio relevant associations, society or alliance or FDA, NHI.  Also be willing to become influencer or contributor or members to these parties for global business and med-tech development collaborations.

3. CRO or Pharma companies for POS & POB collaborations in contract research or tool users

4. Wish to engage with FDA, NHI, Charles Rivers, Crown Bio, US famous BIO medical universities